Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "?Regimen |limit=10000|format=sum}} regimens" to "?Regimen |limit=10000|format=sum}} regimens") |
Warner-admin (talk | contribs) m (Text replacement - "http://onlinelibrary.wiley.com" to "https://onlinelibrary.wiley.com") |
||
| Line 30: | Line 30: | ||
![[Levels_of_Evidence#Evidence|Evidence]] | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[ | + | |[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14966/full Nozza et al. 2017] |
|style="background-color:#ffffbe"|Phase II, <20 pts | |style="background-color:#ffffbe"|Phase II, <20 pts | ||
|- | |- | ||
| Line 46: | Line 46: | ||
===References=== | ===References=== | ||
| − | # Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. [ | + | # Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14966/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29048107 PubMed] |
[[Category:POEMS regimens]] | [[Category:POEMS regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Plasma cell dyscrasias]] | [[Category:Plasma cell dyscrasias]] | ||
Revision as of 17:55, 20 May 2018
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
| Section editor | |
|---|---|
 |
Andrew J. Cowan, MD Seattle, WA |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
All lines of therapy
RD
| back to top |
RD: Revlimid (Lenalidomide) & Dexamethasone
Regimen
| Study | Evidence |
|---|---|
| Nozza et al. 2017 | Phase II, <20 pts |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per week
Supportive medications
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO BID two days per week
Monthly cycles, continued until progression or excess toxicity
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed